 |
answer text |
<p><del class="ministerial">The early access to medicines scheme (EAMS) aims to give
patients with life threatening or seriously debilitating conditions access to medicines
that do not yet have a marketing authorisation when there is a clear unmet medical
need.</del></p><p><del class="ministerial">Under the scheme, the Medicines and Healthcare
products Regulatory Agency (MHRA) will give a scientific opinion on the benefit/risk
balance of the medicine, based on the data available when the EAMS submission was
made and the EAMS criteria. The MHRA will make an evaluation of products, including
drugs such as for brain tumour treatments, once an application is received.</del></p><p><del
class="ministerial">If we do receive an application, it is only made public where
an EAMS Scientific Opinion (SO) is awarded. All EAMS SOs are published on the EAMS
webpage. All drugs that have previously held an EAMS SO are also published on the
EAMS webpage.</del></p><p><ins class="ministerial">The Pharmacy Access Scheme provides
additional funding to pharmacies where the next nearest pharmacy is more than a 20-minute
walk away. This is calculated as a 0.8-mile walking distance in areas of high deprivation
and 1 mile in other areas. In 2021, we agreed updated eligibility criteria and an
updated payment model with Community Pharmacy England. To be eligible for the payment,
pharmacies must deliver the Community Pharmacist Consultation Service. Quality and
opening hours are not included in the eligibility criteria.</ins></p><p> </p><p> </p>
|
|
